ATC classification. Antineoplastic and immunomodulating agents
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01A ALKYLATING AGENTS
L01AA Nitrogen mustard analogues
L01AA01 — cyclophosphamide (, ATC/DDD)
L01AA02 — chlorambucil (, ATC/DDD)
L01AA03 — melphalan (, ATC/DDD)
L01AA05 — chlormethine (, ATC/DDD)
L01AA06 — ifosfamide (, ATC/DDD)
L01AA09 — bendamustine (, ATC/DDD)
L01AB01 — busulfan (, ATC/DDD)
L01AB02 — treosulfan (, ATC/DDD)
L01AC01 — thiotepa (, ATC/DDD)
L01AD01 — carmustine (, ATC/DDD)
L01AD02 — lomustine (, ATC/DDD)
L01AX03 — temozolomide (, ATC/DDD)
L01AX04 — dacarbazine (, ATC/DDD)
L01B ANTIMETABOLITES
L01BA01 — methotrexate (, ATC/DDD)
L01BA03 — raltitrexed (, ATC/DDD)
L01BA04 — pemetrexed (, ATC/DDD)
L01BA05 — pralatrexate% (, ATC/DDD)
L01BB02 — mercaptopurine (, ATC/DDD)
L01BB03 — tioguanine (, ATC/DDD)
L01BB04 — cladribine (, ATC/DDD)
L01BB05 — fludarabine (, ATC/DDD)
L01BB06 — clofarabine (, ATC/DDD)
L01BB07 — nelarabine (, ATC/DDD)
L01BC01 — cytarabine (, ATC/DDD)
L01BC02 — fluorouracil (, ATC/DDD)
L01BC05 — gemcitabine (, ATC/DDD)
L01BC06 — capecitabine (, ATC/DDD)
L01BC07 — azacitidine (, ATC/DDD)
L01BC08 — decitabine (, ATC/DDD)
L01BC52 — fluorouracil, combinations (, ATC/DDD)
L01BC58 — decitabine, combinations (, ATC/DDD)
L01BC59 — trifluridine, combinations (, ATC/DDD)
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01CA Vinca alkaloids and analogues
L01CA01 — vinblastine (, ATC/DDD)
L01CA02 — vincristine (, ATC/DDD)
L01CA04 — vinorelbine (, ATC/DDD)
L01CB Podophyllotoxin derivatives
L01CB01 — etoposide (, ATC/DDD)
L01CD01 — paclitaxel (, ATC/DDD)
L01CD02 — docetaxel (, ATC/DDD)
L01CD04 — cabazitaxel (, ATC/DDD)
L01CE Topoisomerase 1 (TOP1) inhibitors
L01CE01 — topotecan (, ATC/DDD)
L01CE02 — irinotecan (, ATC/DDD)
L01CX Other plant alkaloids and natural products
L01CX01 — trabectedin (, ATC/DDD)
L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01DA01 — dactinomycin (, ATC/DDD)
L01DB Anthracyclines and related substances
L01DB01 — doxorubicin (, ATC/DDD)
L01DB02 — daunorubicin (, ATC/DDD)
L01DB03 — epirubicin (, ATC/DDD)
L01DB06 — idarubicin (, ATC/DDD)
L01DB07 — mitoxantrone (, ATC/DDD)
L01DC Other cytotoxic antibiotics
L01DC01 — bleomycin (, ATC/DDD)
L01DC03 — mitomycin (, ATC/DDD)
L01E PROTEIN KINASE INHIBITORS
L01EA BCR-ABL tyrosine kinase inhibitors
L01EA01 — imatinib (, ATC/DDD)
L01EA02 — dasatinib (, ATC/DDD)
L01EA03 — nilotinib (, ATC/DDD)
L01EA04 — bosutinib (, ATC/DDD)
L01EA05 — ponatinib (, ATC/DDD)
L01EA06 — asciminib (, ATC/DDD)
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01EB01 — gefitinib (, ATC/DDD)
L01EB02 — erlotinib (, ATC/DDD)
L01EB03 — afatinib (, ATC/DDD)
L01EB04 — osimertinib (, ATC/DDD)
L01EC B-Raf serine-threonine kinase (BRAF) inhibitors
L01EC01 — vemurafenib (, ATC/DDD)
L01EC02 — dabrafenib (, ATC/DDD)
L01EC03 — encorafenib (, ATC/DDD)
L01ED Anaplastic lymphoma kinase (ALK) inhibitors
L01ED01 — crizotinib (, ATC/DDD)
L01ED02 — ceritinib (, ATC/DDD)
L01ED03 — alectinib (, ATC/DDD)
L01ED04 — brigatinib (, ATC/DDD)
L01ED05 — lorlatinib (, ATC/DDD)
L01EE Mitogen-activated protein kinase (MEK) inhibitors
L01EE01 — trametinib (, ATC/DDD)
L01EE02 — cobimetinib (, ATC/DDD)
L01EE03 — binimetinib (, ATC/DDD)
L01EE04 — selumetinib (, ATC/DDD)
L01EF Cyclin-dependent kinase (CDK) inhibitors
L01EF01 — palbociclib (, ATC/DDD)
L01EF02 — ribociclib (, ATC/DDD)
L01EF03 — abemaciclib (, ATC/DDD)
L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors
L01EG01 — temsirolimus (, ATC/DDD)
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EH01 — lapatinib (, ATC/DDD)
L01EH02 — neratinib (, ATC/DDD)
L01EH03 — tucatinib (, ATC/DDD)
L01EJ Janus-associated kinase (JAK) inhibitors
L01EJ01 — ruxolitinib (, ATC/DDD)
L01EJ02 — fedratinib (, ATC/DDD)
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
L01EK01 — axitinib (, ATC/DDD)
L01EL Bruton's tyrosine kinase (BTK) inhibitors
L01EL01 — ibrutinib (, ATC/DDD)
L01EL02 — acalabrutinib (, ATC/DDD)
L01EL03 — zanubrutinib (, ATC/DDD)
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
L01EM01 — idelalisib (, ATC/DDD)
L01EM03 — alpelisib (, ATC/DDD)
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
L01EN01 — erdafitinib (, ATC/DDD)
L01EN02 — pemigatinib (, ATC/DDD)
L01EX Other protein kinase inhibitors
L01EX01 — sunitinib (, ATC/DDD)
L01EX02 — sorafenib (, ATC/DDD)
L01EX03 — pazopanib (, ATC/DDD)
L01EX04 — vandetanib (, ATC/DDD)
L01EX05 — regorafenib (, ATC/DDD)
L01EX07 — cabozantinib (, ATC/DDD)
L01EX08 — lenvatinib (, ATC/DDD)
L01EX09 — nintedanib (, ATC/DDD)
L01EX10 — midostaurin (, ATC/DDD)
L01EX12 — larotrectinib (, ATC/DDD)
L01EX13 — gilteritinib (, ATC/DDD)
L01EX14 — entrectinib (, ATC/DDD)
L01EX17 — capmatinib (, ATC/DDD)
L01EX19 — ripretinib (, ATC/DDD)
L01EX21 — tepotinib (, ATC/DDD)
L01EX22 — selpercatinib (, ATC/DDD)
L01EX23 — pralsetinib (, ATC/DDD)
L01EX27 — capivasertib (, ATC/DDD)
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FA CD20 (Clusters of Differentiation 20) inhibitors
L01FA01 — rituximab (, ATC/DDD)
L01FA03 — obinutuzumab (, ATC/DDD)
L01FB CD22 (Clusters of Differentiation 22) inhibitors
L01FB01 — inotuzumab ozogamicin (, ATC/DDD)
L01FC CD38 (Clusters of Differentiation 38) inhibitors
L01FC01 — daratumumab (, ATC/DDD)
L01FC02 — isatuximab (, ATC/DDD)
L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01FD01 — trastuzumab (, ATC/DDD)
L01FD02 — pertuzumab (, ATC/DDD)
L01FD03 — trastuzumab emtansine (, ATC/DDD)
L01FD04 — trastuzumab deruxtecan (, ATC/DDD)
L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
L01FE01 — cetuximab (, ATC/DDD)
L01FE02 — panitumumab (, ATC/DDD)
L01FF PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
L01FF01 — nivolumab (, ATC/DDD)
L01FF02 — pembrolizumab (, ATC/DDD)
L01FF03 — durvalumab (, ATC/DDD)
L01FF04 — avelumab (, ATC/DDD)
L01FF05 — atezolizumab (, ATC/DDD)
L01FF06 — cemiplimab (, ATC/DDD)
L01FF07 — dostarlimab (, ATC/DDD)
L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
L01FG01 — bevacizumab (, ATC/DDD)
L01FG02 — ramucirumab (, ATC/DDD)
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX02 — gemtuzumab ozogamicin (, ATC/DDD)
L01FX04 — ipilimumab (, ATC/DDD)
L01FX05 — brentuximab vedotin (, ATC/DDD)
L01FX06 — dinutuximab beta (, ATC/DDD)
L01FX07 — blinatumomab (, ATC/DDD)
L01FX09 — mogamulizumab (, ATC/DDD)
L01FX12 — tafasitamab (, ATC/DDD)
L01FX13 — enfortumab vedotin (, ATC/DDD)
L01FX14 — polatuzumab vedotin (, ATC/DDD)
L01FX17 — sacituzumab govitecan (, ATC/DDD)
L01FX18 — amivantamab (, ATC/DDD)
L01FX20 — tremelimumab (, ATC/DDD)
L01FX24 — teclistamab (, ATC/DDD)
L01FX27 — epcoritamab (, ATC/DDD)
L01FX28 — glofitamab (, ATC/DDD)
L01FX32 — elranatamab (, ATC/DDD)
L01FY Combinations of monoclonal antibodies and antibody drug conjugates
L01FY01 — pertuzumab and trastuzumab (, ATC/DDD)
L01FY02 — nivolumab and relatlimab (, ATC/DDD)
L01X OTHER ANTINEOPLASTIC AGENTS
L01XA01 — cisplatin (, ATC/DDD)
L01XA02 — carboplatin (, ATC/DDD)
L01XA03 — oxaliplatin (, ATC/DDD)
L01XB01 — procarbazine (, ATC/DDD)
L01XD Sensitizers used in photodynamic/radiation therapy
L01XD03 — methyl aminolevulinate (, ATC/DDD)
L01XD04 — aminolevulinic acid (, ATC/DDD)
L01XF Retinoids for cancer treatment
L01XF01 — tretinoin (, ATC/DDD)
L01XG01 — bortezomib (, ATC/DDD)
L01XG02 — carfilzomib (, ATC/DDD)
L01XG03 — ixazomib (, ATC/DDD)
L01XH Histone deacetylase (HDAC) inhibitors
L01XH01 — vorinostat (, ATC/DDD)
L01XH02 — romidepsin (, ATC/DDD)
L01XJ Hedgehog pathway inhibitors
L01XJ01 — vismodegib (, ATC/DDD)
L01XJ02 — sonidegib (, ATC/DDD)
L01XJ03 — glasdegib (, ATC/DDD)
L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
L01XK01 — olaparib (, ATC/DDD)
L01XK02 — niraparib (, ATC/DDD)
L01XK52 — niraparib and abiraterone (, ATC/DDD)
L01XL Antineoplastic cell and gene therapy
L01XL03 — axicabtagene ciloleucel (, ATC/DDD)
L01XL04 — tisagenlecleucel (, ATC/DDD)
L01XL06 — brexucabtagene autoleucel (, ATC/DDD)
L01XX Other antineoplastic agents
L01XX02 — asparaginase (, ATC/DDD)
L01XX05 — hydroxycarbamide (, ATC/DDD)
L01XX23 — mitotane (, ATC/DDD)
L01XX24 — pegaspargase (, ATC/DDD)
L01XX27 — arsenic trioxide (, ATC/DDD)
L01XX35 — anagrelide (, ATC/DDD)
L01XX41 — eribulin (, ATC/DDD)
L01XX52 — venetoclax (, ATC/DDD)
L01XX66 — selinexor (, ATC/DDD)
L01XX69 — lurbinectedin (, ATC/DDD)
L01XX73 — sotorasib (, ATC/DDD)
L01XX74 — belzutifan (, ATC/DDD)
L01XX75 — tebentafusp (, ATC/DDD)
L01XY Combinations of antineoplastic agents
L01XY01 — cytarabine and daunorubicin (, ATC/DDD)
L02 ENDOCRINE THERAPY
L02A HORMONES AND RELATED AGENTS
L02AB01 — megestrol (, ATC/DDD)
L02AE Gonadotropin releasing hormone analogues
L02AE01 — buserelin (, ATC/DDD)
L02AE02 — leuprorelin (, ATC/DDD)
L02AE03 — goserelin (, ATC/DDD)
L02AE04 — triptorelin (, ATC/DDD)
L02B HORMONE ANTAGONISTS AND RELATED AGENTS
L02BA01 — tamoxifen (, ATC/DDD)
L02BA03 — fulvestrant (, ATC/DDD)
L02BB01 — flutamide (, ATC/DDD)
L02BB03 — bicalutamide (, ATC/DDD)
L02BB04 — enzalutamide (, ATC/DDD)
L02BB05 — apalutamide (, ATC/DDD)
L02BB06 — darolutamide (, ATC/DDD)
L02BG03 — anastrozole (, ATC/DDD)
L02BG04 — letrozole (, ATC/DDD)
L02BG06 — exemestane (, ATC/DDD)
L02BX Other hormone antagonists and related agents
L02BX02 — degarelix (, ATC/DDD)
L02BX03 — abiraterone (, ATC/DDD)
L02BX04 — relugolix (, ATC/DDD)
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AA Colony stimulating factors
L03AA02 — filgrastim (, ATC/DDD)
L03AA13 — pegfilgrastim (, ATC/DDD)
L03AB07 — interferon beta-1a (, ATC/DDD)
L03AB08 — interferon beta-1b (, ATC/DDD)
L03AB11 — peginterferon alfa-2a (, ATC/DDD)
L03AB13 — peginterferon beta-1a (, ATC/DDD)
L03AC01 — aldesleukin (, ATC/DDD)
L03AX03 — bcg vaccine (, ATC/DDD)
L03AX13 — glatiramer acetate (, ATC/DDD)
L03AX16 — plerixafor (, ATC/DDD)
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AA Selective immunosuppressants
L04AA03 — antilymphocyte immunoglobulin (horse) (, ATC/DDD)
L04AA04 — antithymocyte immunoglobulin (rabbit) (, ATC/DDD)
L04AA06 — mycophenolic acid (, ATC/DDD)
L04AA24 — abatacept (, ATC/DDD)
L04AA32 — apremilast (, ATC/DDD)
L04AA40* — cladribine (, ATC/DDD)
L04AA48 — belumosudil (, ATC/DDD)
L04AA58 — efgartigimod alfa (, ATC/DDD)
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB01 — etanercept (, ATC/DDD)
L04AB02 — infliximab (, ATC/DDD)
L04AB04 — adalimumab (, ATC/DDD)
L04AB05 — certolizumab pegol (, ATC/DDD)
L04AB06 — golimumab (, ATC/DDD)
L04AC02 — basiliximab (, ATC/DDD)
L04AC03 — anakinra (, ATC/DDD)
L04AC05 — ustekinumab (, ATC/DDD)
L04AC07 — tocilizumab (, ATC/DDD)
L04AC08 — canakinumab (, ATC/DDD)
L04AC10 — secukinumab (, ATC/DDD)
L04AC11 — siltuximab (, ATC/DDD)
L04AC12 — brodalumab (, ATC/DDD)
L04AC13 — ixekizumab (, ATC/DDD)
L04AC14 — sarilumab (, ATC/DDD)
L04AC16 — guselkumab (, ATC/DDD)
L04AC17 — tildrakizumab (, ATC/DDD)
L04AC18 — rizankizumab (, ATC/DDD)
L04AC19 — satralizumab (, ATC/DDD)
L04AC21 — bimekizumab (, ATC/DDD)
L04AC22 — spesolimab (, ATC/DDD)
L04AC24 — mirikizumab (, ATC/DDD)
L04AD01 — ciclosporin (, ATC/DDD)
L04AD02 — tacrolimus (, ATC/DDD)
L04AE Sphingosine-1-phosphate (S1P) receptor modulators
L04AE01 — fingolimod (, ATC/DDD)
L04AE02 — ozanimod (, ATC/DDD)
L04AE03 — siponimod (, ATC/DDD)
L04AE04 — ponesimod (, ATC/DDD)
L04AE05 — etrasimod (, ATC/DDD)
L04AF Janus-associated kinase (JAK) inhibitors
L04AF01 — tofacitinib (, ATC/DDD)
L04AF02 — baricitinib (, ATC/DDD)
L04AF03 — upadacitinib (, ATC/DDD)
L04AF07 — deucravacitinib (, ATC/DDD)
L04AF08 — ritlecitinib (, ATC/DDD)
L04AG03 — natalizumab (, ATC/DDD)
L04AG04 — belimumab (, ATC/DDD)
L04AG05 — vedolizumab (, ATC/DDD)
L04AG06 — alemtuzumab (, ATC/DDD)
L04AG08 — ocrelizumab (, ATC/DDD)
L04AG10 — inebilizumab (, ATC/DDD)
L04AG11 — anifrolumab (, ATC/DDD)
L04AG12 — ofatumumab (, ATC/DDD)
L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors
L04AH01 — sirolimus (, ATC/DDD)
L04AH02 — everolimus (, ATC/DDD)
L04AJ01 — eculizumab (, ATC/DDD)
L04AJ02 — ravulizumab (, ATC/DDD)
L04AJ03 — pegcetacoplan (, ATC/DDD)
L04AJ05 — avacopan (, ATC/DDD)
L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors
L04AK01 — leflunomide (, ATC/DDD)
L04AK02 — teriflunomide (, ATC/DDD)
L04AX Other immunosuppressants
L04AX01 — azathioprine (, ATC/DDD)
L04AX02 — thalidomide (, ATC/DDD)
L04AX03 — methotrexate (, ATC/DDD)
L04AX04 — lenalidomide (, ATC/DDD)
L04AX05 — pirfenidone (, ATC/DDD)
